


PROGRAM


Wednesday 31 October

9:00am– 9:20am	Welcome to AusBiotech 2018 The Honourable Anastacia Palaszczuk , Premier of Queensland (invited) Lorraine Chiroiu , Chief Executive Officer, AusBiotech			
9:20am– 10:00am	Keeping the balance in your clinical portfolio - prioritisation versus doing it all Dr Charmaine Gittleston , Chief Medical Officer, CSL Limited			
10:00am– 10:30am	Global life science investing & industry update John Carroll , Editor in Chief, Endpoints			
10:30am– 11:00am	Morning tea & networking with exhibitors in the exhibition hall			
11:00am– 12:30pm	Precision medicines: maintaining competitiveness in the post-human genome project era <i>This session will discuss the progression of precision medicines onto to the Australian market, implications for the industry & strategies to help Australian companies maintain global competitiveness in the post-human genome project era</i> Dr Lisette Pregeli , UQ Post-doctoral Research Fellow, The University of Queensland Business School Assoc Prof Damian Hine , Strategy, The University of Queensland Business School	The anatomy of a deal <i>This session provides valuable insights from a spectrum of stakeholders with experience in developing complex deals with multinationals in licensing, providing a service or a product</i> Dr Janette Dixon , Chief Executive Officer/Principal, BioComm Pacific Dr Andrew Kelly , Executive Director, BioPacific Partners Siddharth Shah , Director - External Innovations, Asia Pacific, Zoetis Dr Birgit Reitmaier , Head of Access to Innovation APAC, Merck	Regenerative Medicine Stream A strategic view of the regenerative medicine landscape <i>This session will aim to explore the scientific & regulatory challenges related to progressing cell & gene therapies, highlighting recent scientific, regulatory & launch experience</i> Chair: Dr Tim Oldham , Executive Leader, Tijan Ventures Prof Michael Jensen , Director Pediatrics, Division of Hematology & Oncology, Seattle Children’s Hospital (invited) Dr Tim Farries , Director of Regulatory Affairs for Cell & Gene Therapy Products, ERA Consulting UK	Agriculture & Agtech Stream Gene technologies <i>‘GMO’ has been a disrupter in the way agriculture is produced but, with the advancement of gene editing technologies such as CRISPR, are GMOs now becoming redundant? New innovations in gene technologies & nanotech & current & future application in agriculture</i> Chair: Mike Pointon , General Manager Innovation & Development, Nufarm Ltd Prof Peter Waterhouse , Professor of Molecular Genetics, Science & Engineering Faculty, Earth, Environmental & Biological Sciences, Bioscience, Queensland University of Technology




TropAg2019
International Tropical Agriculture Conference

<p>3:00pm–3:30pm</p>	<p>Afternoon tea & networking with exhibitors in the exhibition hall</p>			
<p>3:30pm–5:00pm</p>	<p>New gene technology in diagnostics, vaccines & CAR-T therapies Chair: Kylie Sproston, Chief Executive, Bellberry Limited Dr Michelle Fraser, CEO & Managing Director, Reproductive Health Science Limited Dr Preethi Eldi, Research Fellow School of Pharmacy & Medical Sciences, UniSA Dr Janet Macpherson, Development Manager, Cell & Molecular Therapies, Royal Prince Alfred Hospital</p>	<p>Your company’s first IND: getting to and through FDA <i>This session is aimed at helping small teams successfully prepare for the process of building & submitting an IND & to establish a productive, collaborative relationship with FDA</i> Chair: Tba Evan Shave, Associate Director, Global Tech Transfer, Process Engineering & Validation, Patheon</p> 	<p><u>Regenerative Medicine Stream</u> Building regenerative medicine industries – international perspectives <i>An account of how different countries are advancing their regenerative medicine activities, in particular the government and regulatory settings to support regenerative medicine advances</i> Chair: Sue MacLeman, Chair, MTPConnect Ltd Korea spotlight: Dr So Ra Park, Director/Professor, Strategic Center for Regenerative Medicine/Inha University Japan spotlight: Dr Fusako Nishigaki, Vice Chair, Steering Committee, Forum for Innovative Regenerative Medicine (FIRM) Israel spotlight: Dr Shir Mnuchin, VP, Partnerships Connecting Industry, Academia & Government, Bioforum Ltd. Canada spotlight: Dr Michael May, President & Chief Executive Officer, CCRM</p>	<p><u>Agriculture & Agtech Stream</u> Food & health <i>Recent achievements and future prospects in development & deregulation of GM foods for improved human health</i> Chair: Dr Allan Green, Innovation Leader, Agriculture & Food, CSIRO Dr James Petrie, Research Scientist, CSIRO Dist Prof James Dale, Professor, Institute for Future Environments, Qld University of Technology Prof Mike Gidley, Director, Centre for Nutrition & Food Sciences, QAAFI, The University of Queensland</p> <p>TropAg2019 International Tropical Agriculture Conference</p>

			Belgium spotlight: Roland Gordon-Beresford, Chief RA/IP Officer, Novadip Biosciences 	
5:30pm–7:00pm	AusBiotech 2018 welcome reception in the exhibition hall			





Thursday 1 November



9:00am–9:45am	Millis Oration Chair: Dr Andrea Douglas, Vice President, R&D Strategy & External Affairs, CSL Limited <i>The three pillars of WEHI’s activities – science, translation & entrepreneurship</i> Prof Doug Hilton, Institute Director, Division Head of Molecular Medicine, Walter & Eliza Hall Institute 	
9:45am–10:30am	Immunology/Oncology – recent advances <i>Now one of the major approaches in the treatment of cancer & autoimmune diseases. Remarkable clinical results with GM cellular therapies (CAR-T) & antibodies against immune checkpoints (CTLA-4, PD-1), have led to successful regulatory approval. The next phase of clinical development will include combination immunotherapies consisting of both cellular & antibody therapeutics. The panel will discuss the latest advances & how novel immunotherapeutic products can be progressed through developmental models & implemented in clinical settings</i> Chair: Prof Rajiv Khanna, Senior Scientist, QIMR Berghofer Panel: Denis Patrick, VP of External Innovation & Science (oncology), Pfizer Dr Michael Rosenzweig, Executive Director, Tumor Immunotherapy, Merck Dr Goslik Schepers, Investment Manager, Brandon Capital Partners	Gender diversity in Australian biotech <i>#metoo - A closer look at women in leadership positions, exploring how Australia measures up in terms of women in senior roles, questioning the progress & issues facing women in life sciences</i> Panel: Sue Charles, Managing Partner, Instinctif Partners Stuart Roberts, Senior Analyst, NDF Research Samantha Cobb, Chief Executive Officer, AdAlta Dr Amanda Gillon, Investment Manager, Bioscience Managers Dr Krystal Evans, Chief Executive Officer, BioMelbourne Network John Carroll, Editor in Chief, Endpoints Diana Sternfeld, Partner, Fieldfisher



10.30am-11.00am Morning tea & networking with exhibitors in the exhibition hall

<p>11:00am–12:30pm</p>	<p>Commercialising medicinal cannabis in Australia’s evolving regulatory environment <i>Medical cannabis is legalised in many countries & approved in Australia in late 2016. A number of medical conditions can be treated with cannabis extracts including chronic pain & chemotherapy nausea. There is patient confusion & frustration as the first companies navigate the complex regulatory environment & gain medical acceptance through doctor education. This session will outline the opportunity & progress in getting quality medical cannabis to Australian patient</i> Chair: Dr Stewart Washer, VP Business Development, Auscann Elaine Darby, Chief Executive Officer, AusCann Peter Crock, Chief Executive Officer, Cann Group Prof Cameron Scadding, Executive Chairman, Source Certain International</p>	<p>From bench to bedside: GPCR drug discovery <i>Despite significant market size, over 80% of GPCR targets are yet to be effectively exploited. This session will explore GPCRs in a number of therapeutic areas</i> Samantha Cobb, Chief Executive Officer, AdAlta Assoc Prof Kevin Pflieger, Chief Scientific Adviser, Dimerix Ltd Dr Chris Langmead, Head, Servier Drug Discovery Program, Monash Institute of Pharmaceutical Services</p>	<p>Early stage investment 6 x 12 min presentations Chair: Glenn Cross, AusEvents Business Development Manager, AusBiotech 11:00-11:15am Queensland ministerial speaker  </p>	<p>Clinical Trials Stream Harness the power of data for smarter drug development <i>Today, clinical trials are accommodating an incredible variety of data & content from various sources – from traditional clinical data, to high-resolution images, operational data & much more. As clinical trials become more complex, the biggest challenge for stakeholders is to reduce study risk, meet complex regulatory requirements, & reduce the life cycle of the clinical development without compromising the patient’s experience</i> Eunho Shin, Head of Solution Consultant in APAC, Medidata Mark Maclean, Head Clinical Data Management, NHMRC Clinical Trial Centre, University of Sydney Dr Anthony Good, Vice President, Clinical Research, Imugene Dr Thomas Polasek, Medical Director, Certara</p>
------------------------	--	---	---	--

	<p>Emily Rigby, Director of Research Programs, Australian Institute for Medical Cannabis</p> <p>Matt Spitzer, Program Coordinator, Oncology Clinical Trials, Mater Research</p>			
12:30pm-1:30pm Lunch & networking with exhibitors in the exhibition hall				
<p>1:30pm–3:00pm</p>	<p>Accelerating the path from bench to biotech: focusing on entrepreneurship to drive innovation</p> <p><i>The effect of building entrepreneurial capability in academic researchers has on transforming the innovation environment with a change in rate of research translation impact</i></p> <p>Panel:</p> <p>Dougal Edwards, Chief Executive Officer, Bright Arena</p> <p>Prof Darren Kelly, Chief Executive Officer & Managing Director, Occurx</p> <p>Dr Rob Grenfell, Health Director, Health & Biosecurity, CSIRO</p> <p>Dr Kath Giles, Investment Manager, Brandon Capital</p>	<p>The rise of Australian & Chinese healthcare industries: regulation & new technologies</p> <p><i>Outline of important regulatory changes in Australia & China affecting manufacturers & suppliers of pharmaceuticals & medical devices that accompany rapid growth</i></p> <p>Chair: Kim O’Connell, Partner, King & Wood Mallesons</p> <p>Esther Hao, Registered Foreign Lawyer, King & Wood Mallesons</p> <p>Anna Feros, Special Counsel, King & Wood Mallesons</p> <p>Dr Mike Skalsky, Managing Director, Sci2Rx Pty Ltd</p> <p>Brent Maxwell, Amazon Web Services</p> 	<p>Early stage investment</p> <p>7 x 12 min presentations</p> <p>Chair: Glenn Cross, AusBiotech</p> 	<p>Clinical Trials Stream</p> <p>Keys to winning clinical trial tenders in Australia</p> <p><i>Discussing how to attract sponsors from a Central Lab perspective, the importance of strategic partnerships & attracting sponsors from a CRO perspective & presenting on facing the issue of our global location & turning it into a positive through planning (lane validation, packaging, transit times, infrastructure, population etc)</i></p> <p>Panel:</p> <p>Brent McPherson, National Business Development Manager, World Courier</p> <p>Paulette Azar-Tannous, Chief Executive Officer, Sonic Clinical Trials</p> <p>Dr Michael Winlo, Chief Executive Officer, Linear</p> 


3:00pm – 3:30pm	Afternoon tea & networking with exhibitors in the exhibition hall			
3:30pm – 5:00pm	<p>Curing paralysis – what innovations do we need to accelerate delivery of an effective therapy <i>Repairing a paralysed spinal cord has long been considered impossible, but now innovative technologies are now making this a reality. This session will highlight the demands & needs of the innovation pathway from patient through to advanced digital solutions</i></p> <p>Chair: Assoc Prof James St John, Head, Clem Jones Centre for Neurobiology & Stem Cell Research, Griffith University Perry Cross, Executive President, Perry Cross Spinal Research Foundation Dr Brent McMonagle, ENT Surgeon, Gold Coast University Hospital Assoc Prof James St John, Head, Clem Jones Centre for Neurobiology & Stem Cell Research, Griffith University Genny Kroll-Rosen, Clinical Operations Manager, Making Strides Prof David Lloyd, Chair, Gold Coast Orthopaedics Research & Education Alliance</p>	<p>The anatomy of a clinical trials claim <i>A claim made by a patient suffering serious injury in a clinical trial can have a significant impact on the business sponsoring the trial. We will discuss what happens when a clinical trial insurance policy is called upon to respond to a demand for compensation from an injured trial participant. Hear from three experts, an insurance company, an insurance broking house & a legal firm</i></p> <p>Chair: Estelle Smith, Life Science Manager, Australia & New Zealand, Chubb Insurance</p> <p>Panel: Scott Jordan, Senior Claims Technical Specialist, Chubb Insurance Shane Aitken, Chief Operating Officer, Avatar Insurance Brokers Karen Jones, Partner, Wotton & Kearney</p> 	<p>Early stage investment 7 x 12 min presentations Chair: Glenn Cross, AusBiotech</p> 	<p>Clinical Trials Stream Niche (neurological) clinical trial capabilities in Australia <i>How we work with biotechnology companies to deliver their project</i> Dr Tina Soulis, General Manager, Neuroscience Trials Australia Dr Andrew Evans, Director of the Movement Disorders Service, Royal Melbourne Hospital Prof Mark Cook, Chair of Medicine, St. Vincent's Hospital Dr Nick Opie, Chief Technology Officer/Founder, Synchron Inc. Dr Rebecca Sheean, Research Coordinator, Fight MND</p>



7:00pm – 11:00pm	Conference dinner at the Grand Chelsea Ballroom at the Mercure Brisbane Hotel			Patheon

Friday 2 November

9:00am– 10:00am	Investor session Chair: Lawrence Gozlan , Portfolio Manager, Scientia Capital Panel: John Carroll , Editor in Chief, Endpoint James leong , Head of IC – Chairman, Pagoda Investment Karimah Es Sabar , Chief Executive Officer & Partner, Quark Venture (invited) Dr Sam Bakri , Global Entrepreneurs Programme UK	Artificial intelligence <i>The future of medical imaging and the basis and future of data mining and artificial intelligence</i> Prof Carolyn Mountford , Chief Executive Officer & Director of Research, Translational Research Institute Dr John Irvine , Chief Scientist for Data Analytics, Draper Laboratory Dr Nic Waddell , Group Leader of Medical Genomics, QIMR Dr David Hansen , Chief Executive Officer & Research Director, CSIRO e-Health Research Program
10:00am– 10:30am	Update on Innovation & Science Australia Dr Charlie Day , Chief Executive Officer, Office of Innovation & Science Australia	
10:30am– 11:00am	Morning tea & networking with exhibitors in the exhibition hall	
11:00am– 12:30pm	Global life sciences outlook: leading in an era of unprecedented change <i>Gain insights on the 2019 outlook for life sciences from pharmaceuticals & biotechnology to diagnostics & digital health with key highlights from geographic, technology, competitive & customer perspectives</i> Chair: Glenn Cross , AusEvents Business Development Manager, AusBiotech Rhenu Bhuller , Partner & SVP, Transformational Health, Frost & Sullivan	Creating investor value – recent Australian public company exits Rob Daniels , Chief Executive Officer, Elastagen Dr Tony Keating , CEO, ResApp David Blake , Founder, Bioshares (invited) Stuart Roberts , Founder & Senior Analyst, NDF Research (invited)

	<p>Mark Dougan, Consulting Director, Transformational Health, Frost & Sullivan Divya Chadha Manek, Head of Business Development, NIHR Clinical Research Network</p> <p style="text-align: center;">F R O S T  S U L L I V A N</p>	
<p>12:30pm– 2:30pm</p>	<p>Lunch, closing ceremony & handover to AusBiotech 2019 in the exhibition hall</p>	